EU regulatory affairs and clinical evaluation
Quint Healthcare supports the clinical and scientific parts of European medical-device and IVD compliance: intended purpose, clinical or performance evaluation, benefit-risk reasoning, post-market evidence and the medical interpretation of regulatory findings.
The service is designed for manufacturers that need more than document production. The central question is whether the clinical argument is coherent across the product claim, available evidence, risk management and post-market plan.
Why this matters now
European medical-device regulation is entering a further period of change. The European Commission proposed a targeted revision of the MDR and IVDR in December 2025 to simplify and digitalise procedures while retaining a high level of patient safety. Because the proposal is not yet settled law, manufacturers need current compliance and evidence plans that remain robust without relying on a future simplification.
For AI-enabled products, regulatory planning must also consider where the EU AI Act, medical-device law and the evidence plan interact. The commercial advantage lies in resolving these interfaces early, before separate workstreams create incompatible assumptions.
When this service is useful
- A notified body has raised findings on a clinical evaluation or the supporting evidence.
- A legacy device or portfolio must be brought into a defensible MDR evidence structure.
- The intended purpose, clinical claims and available data no longer align.
- A PMCF plan exists, but the activity does not answer the residual clinical questions.
- An IVD requires a coherent account of scientific validity, analytical performance and clinical performance.
- Medical-device software or an AI-enabled product must address MDR or IVDR requirements together with applicable EU AI Act obligations.
What we do
Clinical evaluation and performance evaluation
We prepare or review clinical evaluation plans and reports, state-of-the-art analyses, literature strategies, appraisal methods, equivalence arguments and benefit-risk conclusions. For IVDs, the work can cover the clinical and scientific logic of the performance evaluation.
The legal foundation remains the applicable regulation: Regulation (EU) 2017/745 for medical devices and Regulation (EU) 2017/746 for in vitro diagnostic medical devices.
Evidence-gap and finding analysis
Before rewriting, we distinguish between:
- a documentation gap;
- an inconsistency between documents;
- missing or inadequate clinical evidence;
- an intended purpose or claim that the available evidence cannot support.
That distinction determines whether the correct response is a targeted revision, a broader remediation programme, a claim adjustment or additional evidence generation.
PMS and PMCF
We align post-market surveillance and post-market clinical follow-up with the questions left open by the clinical evaluation. Scope may include PMS and PMCF planning, clinical input to periodic reporting, PMCF evaluation and the design of proportionate evidence activities.
Current MDCG guidance and templates are maintained through the European Commission's medical-devices guidance portal. Guidance supports interpretation and implementation, but does not replace the regulations or product-specific judgement.
Medical software and AI
For AI-enabled medical devices and diagnostics, clinical claims, data, human oversight and performance must form one evidence architecture. Regulation (EU) 2024/1689 can apply alongside European medical-device legislation, depending on the product and its classification.
Quint Healthcare addresses the medical and clinical interface. Cybersecurity, QMS implementation, data governance and specialist legal interpretation are integrated through the client's existing functions or appropriate partners.
Deliverables
A project may include:
- clinical evaluation plan or report;
- IVD performance-evaluation input;
- systematic literature strategy and appraisal framework;
- state-of-the-art and benefit-risk analysis;
- clinical evidence-gap assessment;
- PMCF plan or PMCF evaluation;
- clinical review of notified-body findings and response strategy;
- portfolio evidence architecture for related devices;
- workshop with medical, regulatory, risk and product stakeholders.
Relevant experience
The underlying experience includes clinical evaluation and post-market work for medical lasers and optical fibres, evidence and certification work for digital-health products, clinical-study strategy for medical software and sensors, and clinical input to imaging and diagnostic technologies.
This work is led by a physician with a university certificate in medical product regulation and additional training in clinical studies under European medical-device law. It is informed by clinical medicine and pathology as well as translational research and product development.
Boundaries
Quint Healthcare is not a notified body, authorised representative or law firm. It does not replace the manufacturer's quality-management function. The service focuses on clinical and scientific reasoning and works alongside regulatory, quality, technical and legal specialists.
A practical starting point
Clinical file review
We review the intended purpose, clinical claims, current clinical evaluation and PMCF plan, then provide a written assessment of:
- the strongest and weakest parts of the clinical argument;
- whether gaps are primarily documentary or substantive;
- which issues are likely to affect assessment or future evidence;
- a proportionate remediation sequence.
